A prospective cohort study of cytokine levels and circulating DNA in plasma as serological biomarkers of response to immunotherapy in hepatocellular carcinoma
Latest Information Update: 07 Aug 2023
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Durvalumab (Primary) ; Lenvatinib (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Tremelimumab (Primary)
- Indications Liver cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
Most Recent Events
- 24 Jun 2023 Results presented at the European Association for the Study of the Liver Congress 2023
- 24 Aug 2022 New trial record
- 26 Jun 2022 Results presented at The International Liver Congress 2022.